Endothelium and the lipid metabolism: the current understanding.

[1]  J. Liao,et al.  Endothelial function and oxidative stress. , 2004, Endothelium : journal of endothelial cell research.

[2]  C. Stefanadis,et al.  Vasomotor effects of L- and D-arginine in stenotic atheromatous coronary plaque , 2001, Heart.

[3]  C. Napoli,et al.  Involvement of oxidation-sensitive mechanisms in the cardiovascular effects of hypercholesterolemia. , 2001, Mayo Clinic proceedings.

[4]  C. Napoli,et al.  Nitric oxide and atherosclerosis. , 2001, Nitric oxide : biology and chemistry.

[5]  C. Stefanadis,et al.  Therapeutic modification of the L-arginine-eNOS pathway in cardiovascular diseases. , 2001, Atherosclerosis.

[6]  G. Schuler,et al.  Exercise Training in Coronary Artery Disease and Coronary Vasomotion , 2001, Circulation.

[7]  C. Stefanadis,et al.  L-Arginine in coronary atherosclerosis. , 2000, International journal of cardiology.

[8]  E. Feskens,et al.  Arginine Intake and Risk of Coronary Heart Disease Mortality in Elderly Men , 2000, Arteriosclerosis, thrombosis, and vascular biology.

[9]  G. Schuler,et al.  Effect of exercise on coronary endothelial function in patients with coronary artery disease. , 2000, The New England journal of medicine.

[10]  R. Vogel.  Cholesterol lowering and endothelial function. , 1999, The American journal of medicine.

[11]  G. Kojda,et al.  Interactions between NO and reactive oxygen species: pathophysiological importance in atherosclerosis, hypertension, diabetes and heart failure. , 1999, Cardiovascular research.

[12]  W. Graier,et al.  Selective stimulation of L-arginine uptake contributes to shear stress-induced formation of nitric oxide. , 1999, Life sciences.

[13]  M. Grigioni,et al.  ET(A)/ET(B) receptor antagonist bosentan inhibits neointimal development in collared carotid arteries of rabbits. , 1998, Life sciences.

[14]  M. Corretti,et al.  Cholesterol, cholesterol lowering, and endothelial function. , 1998, Progress in cardiovascular diseases.

[15]  R. Cannon.  Role of nitric oxide in cardiovascular disease: focus on the endothelium. , 1998, Clinical chemistry.

[16]  R. Schmieder,et al.  Increased bioavailability of nitric oxide after lipid-lowering therapy in hypercholesterolemic patients: a randomized, placebo-controlled, double-blind study. , 1998, Circulation.

[17]  H. Kosaka,et al.  Role of endogenous endothelin in the development of graft arteriosclerosis in rat cardiac allografts: antiproliferative effects of bosentan, a nonselective endothelin receptor antagonist. , 1998, Circulation.

[18]  G. Plotnick,et al.  The mechanism of improvement in endothelial function by pravastatin: direct effect or through cholesterol lowering , 1998 .

[19]  A. Baron,et al.  Endothelial dysfunction is associated with cholesterol levels in the high normal range in humans. , 1997, Circulation.

[20]  K. Schenck-Gustafsson,et al.  Transient triglyceridemia decreases vascular reactivity in young, healthy men without risk factors for coronary heart disease. , 1997, Circulation.

[21]  M. Creager,et al.  When 'normal' cholesterol levels injure the endothelium. , 1997, Circulation.

[22]  D. Harrison,et al.  Cellular and molecular mechanisms of endothelial cell dysfunction. , 1997, The Journal of clinical investigation.

[23]  W. Erl,et al.  HMG-CoA reductase inhibitors decrease CD11b expression and CD11b-dependent adhesion of monocytes to endothelium and reduce increased adhesiveness of monocytes isolated from patients with hypercholesterolemia. , 1997, Journal of the American College of Cardiology.

[24]  A. Quyyumi,et al.  Effect of L-arginine on human coronary endothelium-dependent and physiologic vasodilation. , 1997, Journal of the American College of Cardiology.

[25]  T. Lüscher,et al.  Biology of the Endothelium , 1997, Clinical cardiology.

[26]  E. Whitney,et al.  Effect of gemfibrozil +/- niacin +/- cholestyramine on endothelial function in patients with serum low-density lipoprotein cholesterol levels <160 mg/dl and high-density lipoprotein cholesterol levels <40 mg/dl. , 1997, The American journal of cardiology.

[27]  R. Schwartz,et al.  Enhanced endothelin-mediated coronary vasoconstriction and attenuated basal nitric oxide activity in experimental hypercholesterolemia. , 1997, Circulation.

[28]  B. Hornig,et al.  Vitamin C improves endothelial dysfunction of epicardial coronary arteries in hypertensive patients. , 1997, Circulation.

[29]  P. Marraccini,et al.  Plasma cholesterol regulates soluble cell adhesion molecule expression in familial hypercholesterolemia. , 1997, Circulation.

[30]  D. Celermajer,et al.  Endothelial dysfunction: does it matter? Is it reversible? , 1997, Journal of the American College of Cardiology.

[31]  T. Saldeen,et al.  Preservation of endogenous antioxidant activity and inhibition of lipid peroxidation as common mechanisms of antiatherosclerotic effects of vitamin E, lovastatin and amlodipine. , 1997, Journal of the American College of Cardiology.

[32]  J. Jukema,et al.  Functional evaluation of lipid-lowering therapy by pravastatin in the Regression Growth Evaluation Statin Study (REGRESS) , 1997, Circulation.

[33]  T. Lehtimäki,et al.  In vivo low density lipoprotein oxidation relates to coronary reactivity in young men. , 1997, Journal of the American College of Cardiology.

[34]  R. Vogel.  Coronary risk factors, endothelial function, and atherosclerosis: A review , 1997, Clinical cardiology.

[35]  G. Assmann,et al.  Low-density lipoproteins inhibit the Na+/H+ antiport in human platelets. A novel mechanism enhancing platelet activity in hypercholesterolemia. , 1997, Circulation.

[36]  D. Green,et al.  Simvastatin, an HMG-coenzyme A reductase inhibitor, improves endothelial function within 1 month. , 1997, Circulation.

[37]  G. Plotnick,et al.  Effect of a single high-fat meal on endothelial function in healthy subjects. , 1997, The American journal of cardiology.

[38]  P. Ganz,et al.  Effect of cholesterol reduction on myocardial ischemia in patients with coronary disease. , 1997, Circulation.

[39]  T. Imaizumi,et al.  Single LDL apheresis improves endothelium-dependent vasodilatation in hypercholesterolemic humans. , 1997, Circulation.

[40]  P. Vanhoutte,et al.  Endothelium-derived hyperpolarizing factor. , 1996, Clinical and experimental pharmacology & physiology.

[41]  M. Petch,et al.  Aging-associated endothelial dysfunction in humans is reversed by L-arginine. , 1996, Journal of the American College of Cardiology.

[42]  H. Superko,et al.  Beyond LDL cholesterol reduction. , 1996, Circulation.

[43]  H. Crijns,et al.  Reduction of transient myocardial ischemia with pravastatin in addition to the conventional treatment in patients with angina pectoris. REGRESS Study Group. , 1996, Circulation.

[44]  A. Yeung,et al.  Endothelium-dependent coronary vasomotion relates to the susceptibility of LDL to oxidation in humans. , 1996, Circulation.

[45]  J. Mehta,et al.  Oxidized LDL decreases L-arginine uptake and nitric oxide synthase protein expression in human platelets: relevance of the effect of oxidized LDL on platelet function. , 1996, Circulation.

[46]  R. Virmani,et al.  Coronary plaque erosion without rupture into a lipid core. A frequent cause of coronary thrombosis in sudden coronary death. , 1996, Circulation.

[47]  C. Ballantyne,et al.  Levels of Soluble Cell Adhesion Molecules in Patients With Dyslipidemia , 1996 .

[48]  P. Ganz,et al.  Atherosclerosis: risk factors and the vascular endothelium. , 1996, American heart journal.

[49]  M. Hori,et al.  Endothelial dysfunction in the early stage of atherosclerosis precedes appearance of intimal lesions assessable with intravascular ultrasound. , 1996, American heart journal.

[50]  D. Waters,et al.  Hyperlipidemia and coronary disease. Correction of the increased thrombogenic potential with cholesterol reduction. , 1995, Circulation.

[51]  A. Quyyumi,et al.  Evidence that endothelial dysfunction in patients with hypercholesterolemia is not due to increased extracellular nitric oxide breakdown by superoxide anions. , 1995, The American journal of cardiology.

[52]  O. Hess,et al.  Exercise-induced vasomotion of angiographically normal and stenotic coronary arteries improves after cholesterol-lowering drug therapy with bezafibrate. , 1995, Journal of the American College of Cardiology.

[53]  N. Mullani,et al.  Changes in myocardial perfusion abnormalities by positron emission tomography after long-term, intense risk factor modification. , 1995, JAMA.

[54]  C. Wanner,et al.  Impairment of endothelium-dependent dilation in rabbit renal arteries by oxidized lipoprotein(a). Role of oxygen-derived radicals. , 1995, Circulation.

[55]  T. Rabelink,et al.  Vascular function in the forearm of hypercholesterolaemic patients off and on lipid-lowering medication , 1995, The Lancet.

[56]  V. Fuster,et al.  Coronary plaque disruption. , 1995, Circulation.

[57]  A. Heagerty,et al.  In vitro responses of human peripheral small arteries in hypercholesterolemia and effects of therapy. , 1995, Circulation.

[58]  P. Libby.  Molecular bases of the acute coronary syndromes. , 1995, Circulation.

[59]  W. Weintraub,et al.  Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease. , 1995, The New England journal of medicine.

[60]  G. Levine,et al.  Cholesterol reduction in cardiovascular disease. Clinical benefits and possible mechanisms. , 1995, The New England journal of medicine.

[61]  A. Yeung,et al.  The effect of cholesterol-lowering and antioxidant therapy on endothelium-dependent coronary vasomotion. , 1995, The New England journal of medicine.

[62]  A. Quyyumi,et al.  Effect of antioxidant vitamins on low density lipoprotein oxidation and impaired endothelium-dependent vasodilation in patients with hypercholesterolemia. , 1994, Journal of the American College of Cardiology.

[63]  D. Celermajer,et al.  Endothelium-dependent dilation in the systemic arteries of asymptomatic subjects relates to coronary risk factors and their interaction. , 1994, Journal of the American College of Cardiology.

[64]  S. Nilsson,et al.  The effect of probucol on femoral atherosclerosis: the Probucol Quantitative Regression Swedish Trial (PQRST). , 1994, The American journal of cardiology.

[65]  V. Maher,et al.  Reversal of coronary heart disease by lipid-lowering therapy. Observations and pathological mechanisms. , 1994, Circulation.

[66]  M. Sugimachi,et al.  Reduction in serum cholesterol with pravastatin improves endothelium-dependent coronary vasomotion in patients with hypercholesterolemia. , 1994, Circulation.

[67]  G. Gibbons,et al.  The emerging concept of vascular remodeling. , 1994, The New England journal of medicine.

[68]  A. Quyyumi,et al.  Investigation of decreased availability of nitric oxide precursor as the mechanism responsible for impaired endothelium-dependent vasodilation in hypercholesterolemic patients. , 1994, Journal of the American College of Cardiology.

[69]  S. Moncada,et al.  The L-arginine-nitric oxide pathway. , 1993, The New England journal of medicine.

[70]  A. Quyyumi,et al.  The Role of Nitric Oxide in Endothelium‐Dependent Vasodilation of Hypercholesterolemic Patients , 1993, Circulation.

[71]  D. Waters,et al.  Plasma Lipoproteins and Progression of Coronary Artery Disease Evaluated by Angiography and Clinical Events , 1993, Circulation.

[72]  O. Hess,et al.  Influence of Serum Cholesterol and Other Coronary Risk Factors on Vasomotion of Angiographically Normal Coronary Arteries , 1993, Circulation.

[73]  C. Lau,et al.  Beneficial effect of cholesterol-lowering therapy on coronary endothelium-dependent relaxation in hypercholesterolaemic patients , 1993, The Lancet.

[74]  D. Harrison,et al.  Hypercholesterolemia increases endothelial superoxide anion production. , 1993, The Journal of clinical investigation.

[75]  J. Albers,et al.  Lipid Lowering and Plaque Regression New Insights Into Prevention of Plaque Disruption and Clinical Events in Coronary Disease , 1993, Circulation.

[76]  K. Hirata,et al.  High density lipoprotein reverses inhibitory effect of oxidized low density lipoprotein on endothelium-dependent arterial relaxation. , 1993, Circulation research.

[77]  A. Quyyumi,et al.  Role of Endothelium‐Derived Nitric Oxide in the Abnormal Endothelium‐Dependent Vascular Relaxation of Patients With Essential Hypertension , 1993, Circulation.

[78]  J. Cooke,et al.  Vascular Biology and Medicine in the 1990s: Scope, Concepts, Potentials, and Perspectives , 1993, Circulation.

[79]  J. Cooke,et al.  L-arginine improves endothelium-dependent vasodilation in hypercholesterolemic humans. , 1992, The Journal of clinical investigation.

[80]  H. Drexler,et al.  Correction of endothelial dysfunction in coronary microcirculation of hypercholesterolaemic patients by L-arginine , 1991, The Lancet.

[81]  E. Mohler,et al.  Effects of high-density lipoprotein on acetylcholine-induced coronary vasoreactivity. , 1991, The American journal of cardiology.

[82]  A. Lerman,et al.  Circulating and tissue endothelin immunoreactivity in advanced atherosclerosis. , 1991, The New England journal of medicine.

[83]  R. Lawn,et al.  Lipoprotein(a) and atherosclerosis. , 1991, Annals of internal medicine.

[84]  K. Margulies,et al.  Endothelin: a new cardiovascular regulatory peptide. , 1990, Mayo Clinic proceedings.

[85]  M J Davies,et al.  A macro and micro view of coronary vascular insult in ischemic heart disease. , 1990, Circulation.

[86]  M. Cybulsky,et al.  Endothelial‐Dependent Mechanisms of Leukocyte Adhesion in Inflammation and Atherosclerosis a , 1990, Annals of the New York Academy of Sciences.

[87]  R. Cohen,et al.  Oxidized low density lipoproteins cause contraction and inhibit endothelium-dependent relaxation in the pig coronary artery. , 1990, The Journal of clinical investigation.

[88]  K. Kugiyama,et al.  Impairment of endothelium-dependent arterial relaxation by lysolecithin in modified low-density lipoproteins , 1990, Nature.

[89]  A. Yeung,et al.  Coronary vasomotor response to acetylcholine relates to risk factors for coronary artery disease. , 1990, Circulation.

[90]  J. Breslow,et al.  Lipoprotein(a) modulation of endothelial cell surface fibrinolysis and its potential role in atherosclerosis , 1989, Nature.

[91]  H. Shimokawa,et al.  Hypercholesterolemia causes generalized impairment of endothelium-dependent relaxation to aggregating platelets in porcine arteries. , 1989, Journal of the American College of Cardiology.

[92]  J L Witztum,et al.  Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity. , 1989, The New England journal of medicine.

[93]  E. Nabel,et al.  Evidence of endothelial dysfunction in angiographically normal coronary arteries of patients with coronary artery disease. , 1989, Circulation.

[94]  A. M. Lefer,et al.  Cardiovascular effects of acute hypercholesterolemia in rabbits. Reversal with lovastatin treatment. , 1989, The Journal of clinical investigation.

[95]  P. Ganz,et al.  Paradoxical vasoconstriction induced by acetylcholine in atherosclerotic coronary arteries. , 1986, The New England journal of medicine.

[96]  M. Gimbrone,et al.  Influence of hemodynamic forces on vascular endothelial function. In vitro studies of shear stress and pinocytosis in bovine aortic cells. , 1984, The Journal of clinical investigation.

[97]  R. Furchgott,et al.  The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine , 1980, Nature.

[98]  W. Sterling Edwards,et al.  Blood Vessels , 1959 .

[99]  T. Lüscher,et al.  Endothelin in atherosclerosis: importance of risk factors and therapeutic implications. , 2000, Journal of cardiovascular pharmacology.

[100]  H. Drexler,et al.  Endothelial Dysfunction in Hypercholesterolemia: Mechanisms, Pathophysiological Importance, and Therapeutic Interventions , 2000, Seminars in thrombosis and hemostasis.

[101]  G. Plotnick,et al.  Changes in flow-mediated brachial artery vasoactivity with lowering of desirable cholesterol levels in healthy middle-aged men. , 1996, The American journal of cardiology.

[102]  T. Lüscher,et al.  Endothelium-Derived Nitric Oxide, Endothelin, and Platelet Vessel Wall Interaction: Alterations in Hypercholesterolemia and Atherosclerosis , 1993, Seminars in thrombosis and hemostasis.

[103]  B. Hoffman,et al.  Inactivation of endothelial derived relaxing factor by oxidized lipoproteins. , 1992, The Journal of clinical investigation.

[104]  S. Mocanda.  THE L-ARGININE-NITRIC OXIDE PATHWAY , 1992 .